Zim Laboratories

What Zim Laboratories does

Zim Laboratories Limited is an Indian pharmaceutical manufacturer incorporated in 1984 (CIN: L99999MH1984PLC032172), headquartered in Nagpur, Maharashtra, with manufacturing operations in Kalmeshwar and a Mumbai business office. Listed on the National Stock Exchange of India since 2022, the company develops and supplies differentiated generic pharmaceutical products in oral solid dosage forms, organized around three core product lines: Pre-Formulation Intermediates (granules, pellets in immediate/modified/delayed release formats, taste-masked powders, dry suspensions), Finished Formulations (tablets and capsules registered as branded generics), and Oral Thin Films (OTF), the company's differentiated and growing segment delivering active pharmaceutical ingredients through rapidly dissolving polymer films. The company also offers nutraceutical products including Orally Disintegrating Strips and pellets under the ZimUnat line.

The company's technical platform rests on proprietary drug delivery technologies developed in an in-house R&D centre recognized by DSIR, Government of India. These include Thinoral (orodispersible film), MucoStrip (buccal mucosa delivery), Spinoral (high-dose film delivery), Pellet Cold Forming Technology for heat-sensitive APIs, Micro-Emulsion Coating, and RGDRT-Enabled Delivery for enhanced bioavailability. Manufacturing facilities hold WHO-GMP, ISO 9001, and NSF/ANSI 455-2 certifications, with regulatory expertise spanning more than 50 countries in regulated, Pharmerging, and ROW markets. Therapeutic focus spans urology, cardiovascular, anti-infectives, gastrointestinal, pain management, central nervous system, and vitamins/supplements.

Zim operates a B2B contract manufacturing and licensing model. Revenue is generated through direct sales to global pharmaceutical and nutraceutical companies, exclusive licensing and co-development agreements with regional marketing partners, and technology transfer support. Key commercial partners include Neuraxpharm (Europe, co-development of Buprenorphine Sublingual Film), Globalpharma Co. (GCC, OTF commercialization announced 2025), and Hypera Pharma Group (Brazil, Vitamin D3 Orally Disintegrating Strips). Recent quarterly performance for the period ending December 2025 shows consolidated sales of ₹108.66 crore (up 12.80% year-over-year) and consolidated net profit of ₹4.40 crore at an 11.79% operating margin. The company is founder-controlled, with Dr. Anwar Daud holding a 25.05% promoter stake following a June 2026 inter-se transfer.

Name

Zim Laboratories

Legal name

ZIM Laboratories Limited

Website

https://zimlab.in

Company type

Public

Founded year

1984

Operating status

Operating

Headcount range

251–500 employees

Short description

Zim Laboratories Limited is an Indian pharmaceutical manufacturer specializing in differentiated generic products and proprietary Oral Thin Film drug delivery technologies. The company serves global pharmaceutical and nutraceutical firms through B2B contract manufacturing, licensing, and exclusive regional distribution partnerships across 50+ countries.

Ownership category

akta.pro rank

Product category

Pharmaceutical Contract Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Contract Development & Manufacturing for Generics (CDMO/CMO) (HLAIABAI)

akta.pro secondary industries

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH), CMC & Pharmaceutical Development (Formulation/Process/Analytical Development) (HLAIALAD)

Keywords

• Pharmaceutical manufacturing
• Differentiated generic formulations
• Oral thin films
• Drug delivery solutions
• Nutraceutical products

Headquarters

HQ city

Nagpur

HQ country

India

HQ region

Asia

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Personnel, Technology or R&D, Operations, Infrastructure, Marketing or Sales

Revenue model

1. Pharmaceutical Manufacturing: Revenue generated from manufacturing and supplying differentiated generic pharmaceutical products in oral solid dosage forms, both as pre-formulation intermediates (PFI) and finished formulations (FF). The company provides comprehensive solutions including product conceptualization, development, BE studies, regulatory support, manufacturing, and supply.
2. Nutraceutical Products: Revenue from manufacturing and supplying nutraceutical products including Orally Disintegrating Strips and pellets, serving the functional wellness and dietary supplement markets.
3. Technology Licensing and Transfer: Revenue from technology transfer support and licensing of proprietary manufacturing processes to enable efficient local manufacturing for partners in regulated, Pharmerging, and ROW markets.
4. Product Registration and Marketing Rights: Revenue from obtaining marketing authorizations for products in various regions (Europe, GCC, etc.) and commercializing through local distribution partners.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels9 records

Core offering

ZIM Laboratories is a research-driven, vertically integrated pharmaceutical manufacturer in India that develops, manufactures, and supplies differentiated generic products in oral solid dosage forms, including Pre-Formulation Intermediates (granules, pellets, taste-masked powders, dry suspensions), Finished Formulations (tablets, capsules), and Oral Thin Films (OTF). The company also offers nutraceutical products and provides end-to-end solutions covering product conceptualization, development, BE studies, regulatory support, registration, manufacturing, and supply to pharmaceutical companies, nutraceutical companies, and distributors globally.

Product overview

ZIM Laboratories is a vertically integrated pharmaceutical manufacturer offering differentiated generic products in oral solid dosage forms. The portfolio is organized around three core product lines: Pre-Formulation Intermediates (PFI) providing granules, pellets, taste-masked powders, and dry suspensions; Finished Formulations (FF) encompassing tablets and capsules registered as branded generics; and Oral Thin Films (OTF), a growing segment delivering drugs through rapidly dissolving polymer films. The company also offers a comprehensive nutraceutical line including Orally Disintegrating Strips and Pellets. Underpinning the product portfolio are proprietary drug delivery technologies including Thinoral® Technology for orodispersible films, MucoStrip Technology for buccal delivery, Spinoral Technology for high-dose medications, Pellet Cold Forming Technology for heat-sensitive APIs, Micro-Emulsion Coating Technology, and RGDRT-Enabled Delivery for enhanced bioavailability. Products serve therapeutic areas including urology, cardiovascular, anti-infectives, gastrointestinal, pain management, vitamins/supplements, and central nervous system conditions.

Differentiator

Problem solved

Functional benefit

Brands

• Thinoral Technology: Proprietary oral thin film technology for improved medication absorption with orodispersible films
• Spinoral Technology
• MucoStrip Technology
• ZimUnat

Products and services

• Pre-Formulation Intermediates (PFI) Pharmaceutical formulation intermediates supplied as semi-finished inputs for final dosage form manufacturing, including granules, pellets (immediate-release, modified-release, delayed-release), taste-masked powders, and dry suspensions. Used by pharmaceutical companies building differentiated generic products.
• Finished Formulations (FF) Completed pharmaceutical dosage forms including tablets and capsules registered and marketed as branded generics in select regulated and Pharmerging markets through local distributors and marketing partners.
• Oral Thin Films (OTF) Thin polymer-based films that dissolve rapidly in the oral cavity to deliver APIs through buccal or sublingual pathways, enabling faster onset and improved bioavailability. Used for both pharmaceutical and nutraceutical applications.
• Nutraceutical Products Health supplements and functional wellness products including vitamins, minerals, botanicals, and bioactive compounds, available in oral thin film and other dosage forms.
• Orally Disintegrating Strips (ODS) Thin-film dosage systems that dissolve rapidly when placed on the tongue or oral mucosa, delivering functional ingredients in a convenient oral format without water.
• Pellets Multiparticulate spherical particles used for modified and controlled release applications, enabling precise modulation of drug release profiles with uniform distribution in the gastrointestinal tract.
• New Innovative Products (NIP) - Differentiated Generic Pipeline Proprietary non-infringing drug delivery solutions developed in-house through DSIR-recognized R&D, encompassing differentiated generic products based on innovative process technologies. Includes marketed products such as Di-Methyl Fumarate Modified Release Capsules (Portugal, 2025), Buprenorphine Sublingual Film (Europe, 2025), Azithromycin for Oral Suspension (Portugal, 2025), Sildenafil 50 mg ODS (Spain, 2022), and Rizatriptan marketing rights (Portugal, 2021).
• Products for Regulated Markets Finished formulations and oral thin film products specifically developed and approved for regulated markets including Europe and GCC, meeting stringent regulatory requirements such as EU-GMP standards.

Quantifiable outcome

• 12.80% year-over-year sales increase to Rs 108.66 crore in Q4 December 2025
• +2 more outcomes

Named customers3 records

Segments4 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature8 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Globalpharma Co. (L.L.C.)coreChannel Partner/ Reseller/ Distributor · 1 January 2025ZIM Laboratories Limited and Globalpharma Co. (L.L.C.) announced a strategic collaboration to commercialize Oral Thin Film products in the GCC (Gulf Cooperation Council) Region. This partnership leverages Globalpharma's regional market expertise and distribution capabilities to expand ZIM's OTF product portfolio in the Middle East market.
• Australia and MENA PartnershipsminorChannel Partner/ Reseller/ Distributor · 1 January 2023ZIM Lab invested in key partnerships in Australia and MENA (Middle East and North Africa) regions to expand its global footprint and market presence in these strategic geographic areas.
• Hypera Pharma GroupcoreOEM/ Whitelabel/ Licensing Partner · 1 January 2020ZIM Laboratories Limited entered into an exclusive licensing agreement with Hypera Pharma Group for Vitamin D3 Orally Disintegrating Strips for the Brazil market. ZIM provided the technology and manufacturing capabilities while Hypera handled commercialization in Brazil.
• NeuraxpharmcoreStrategic or Co-development Partner · 1 January 2019ZIM Laboratories Limited and Neuraxpharm entered into an exclusive co-development agreement. The partnership resulted in marketing authorization for Buprenorphine Sublingual Film in Europe, demonstrating ZIM's capabilities in developing complex generic products with innovative drug delivery technologies.

Scale indicators5 records

Recent moves7 records

Expansion highlights5 records

Broad incumbents

• Lupin Limited: Indian global pharmaceutical major with a generics, biosimilars, and specialty portfolio; a relevant scaled peer in Indian generic pharma with strong regulatory reach and CDMO-style operations.
• Cipla Limited: Indian pharmaceutical leader with extensive global generic footprint including complex generics, inhalation, and biosimilars — relevant as a large Indian pharma peer operating in similar regulated and emerging markets.
• Sun Pharmaceutical Industries: Largest Indian specialty generic pharmaceutical company, offering a broad portfolio of branded generics, OTC, and APIs across 100+ countries — comparable to Zim as a leading Indian pharma exporter with global regulatory reach.
• Aurobindo Pharma: Large Indian generic pharmaceutical manufacturer with vertically integrated API-to-finished-dose capabilities, serving global regulated and emerging markets — comparable to Zim as a fellow Indian pharma exporter targeting 50+ countries.
• Dr. Reddy's Laboratories: Major Indian generic pharmaceutical manufacturer with global presence across branded generics, biosimilars, and OTC, offering differentiated formulations including modified-release products — relevant as a scaled peer in Indian generics.
• Hisamitsu Pharmaceutical (Noven division): Japanese pharmaceutical major with a significant OTF/transdermal drug delivery franchise (Noven), relevant as a scaled incumbent in the same film-based drug delivery category that Zim competes in.

Direct peers

• Aquestive Therapeutics: US-based specialty pharma company specializing in oral thin film drug delivery (PharmFilm technology), directly comparable to Zim's Thinoral/MucoStrip/Spinoral OTF franchise for CNS and other therapeutic areas.
• IntelGenx Corp: Canadian specialty pharma company developing oral thin film and other novel drug delivery platforms (VersaFilm), competing in the same differentiated oral film niche as Zim with partner-led commercialization.
• Granules India: Indian pharmaceutical company specializing in finished dosages, PFI, and API manufacturing, with a comparable focus on pre-formulation intermediates, pellets, and paracetamol/ibuprofen formulations for global B2B customers.

Emerging players

• Cure Pharmaceutical (CurePharma): Smaller specialty pharma company focused on novel oral thin film drug delivery (CureFilm), competing directly with Zim in the differentiated OTF space with a partner-led commercialization model.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• Xx.com/zimlab
• YouTubeyoutube.com/channel/UCCDZ7ySr5lGKhFHETfcOH_w
• Facebookfacebook.com/ZIMINDIA
• LinkedInlinkedin.com/company/zim-laboratories-ltd-
• Instagraminstagram.com/zimlaboratories

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Zim Laboratories